What Vimy Pharma does

Vimy Pharma (legal name Vimy Pharmaceuticals Inc.) is a privately held Canadian pharmaceutical manufacturer founded in 2024 and headquartered in Toronto. The company develops and intends to produce high-quality, affordable complex medicines, with its lead and currently only disclosed product being a generic version of semaglutide (generic Ozempic), a GLP-1 receptor agonist indicated for diabetes and obesity. Manufacturing is planned for Canadian facilities (with Edmonton referenced in coverage) under Health Canada quality standards, and the company frames its positioning explicitly around Canadian-made and Canadian-owned production to reduce dependence on foreign pharmaceutical supply.

The business model is product sales of generic pharmaceuticals distributed through a single channel partner: Vimy has outsourced all sales and marketing activities across Canada to Pharmaris Canada under a strategic partnership announced 2025-05-30, giving Vimy nationwide reach without an internal salesforce. End customers are Canadian patients with chronic diseases (diabetes and obesity) and the broader publicly funded healthcare system, with secondary stakeholders including employer plan sponsors bearing the cost of specialty medications. Revenue is not yet generated as products are in development and have not launched; pricing has not been disclosed.

The company is led by co-founders with deep GLP-1 and pharmaceutical finance backgrounds: CEO Dave Suchon (former VP Corporate Affairs at Novo Nordisk Canada who led the first Canadian Ozempic approval in 2018), President and Chair Farris Smith (former CFO at Novo Nordisk and LEO Pharma North America), and COO Chris Burkett (former National Leader, Legal at Deloitte Canada). The board includes operators with pharma (Patheon/Thermo Fisher), real estate, and legal backgrounds. The company has also established a community partnership with Wounded Warriors Canada, pledging a portion of profits, and recorded a funding round with K2 & Associates in October 2025.

Name

Vimy Pharma

Legal name

Vimy Pharmaceuticals Inc.

Website

https://vimypharma.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Vimy Pharma is a Toronto-based private pharmaceutical manufacturer developing a Canadian-made generic version of semaglutide (generic Ozempic) for diabetes and obesity, distributing exclusively through partner Pharmaris Canada to serve Canadian patients and the publicly funded healthcare system.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Generic pharmaceuticals manufacturing
• GLP-1 receptor agonists
• Semaglutide generic drugs
• Diabetes obesity treatments
• Complex medicine manufacturing

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through the sale of generic pharmaceutical products, primarily targeting the Canadian domestic market. The company focuses on essential medicines for chronic diseases including diabetes and obesity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vimy Pharma is a Canadian pharmaceutical manufacturer developing and producing a generic version of semaglutide (generic Ozempic), a GLP-1 therapy indicated for the treatment of type 2 diabetes and obesity. The company focuses on Canadian-made, Canadian-owned manufacturing of complex medicines that meet Health Canada quality and safety guidelines, with sales and marketing executed nationally through a partnership with Pharmaris Canada.

Product overview

Vimy Pharma is a proudly Canadian pharmaceutical company developing and manufacturing high-quality, affordable essential medicines. The company's primary focus is producing a generic version of Ozempic (generic semaglutide) — a GLP-1 medication for diabetes and obesity treatment. The product portfolio centers on this single pharmaceutical offering, with manufacturing planned for Canadian facilities (potentially Edmonton) and sales/marketing handled through a partnership with Pharmaris Canada across Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Semaglutide (Generic Ozempic) A generic version of the blockbuster GLP-1 therapy Ozempic (semaglutide), being developed and manufactured in Canada as a high-quality, affordable treatment for type 2 diabetes and obesity. Targeted at the Canadian domestic market and distributed through a sales and marketing partnership with Pharmaris Canada.

Quantifiable outcome

• Goal of providing affordable access to essential medicines for millions of Canadians

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered minor and core.

• Wounded Warriors CanadaminorGTM or Marketing Partner · 8 July 2025Vimy Pharma announced a partnership with Wounded Warriors Canada, a national leader in mental health services for Veterans, First Responders, and their families. Under this partnership, Vimy Pharma pledges a portion of its profits to support the organization. The partnership reflects Vimy Pharma's commitment to Canadian communities and honors the military heritage reflected in the company's name (Vimy Ridge).
• Pharmaris CanadacoreChannel Partner/ Reseller/ Distributor · 30 May 2025Pharmaris Canada and Vimy Pharma announced a strategic partnership in which Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma's product portfolio across Canada. The collaboration unites two Canadian pharmaceutical organizations with the stated goal of strengthening domestic pharmaceutical capabilities and improving access to essential medicines for Canadian patients. Both companies emphasized their commitment to making healthcare more accessible and affordable from coast to coast.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Others

• Patheon (Thermo Fisher Scientific): CDMO acquired by Thermo Fisher with deep expertise in complex pharmaceutical manufacturing including peptides. Comparable as a potential manufacturing partner or contract manufacturer for Vimy's complex generic portfolio, and a connection through Vimy board member Riccardo Trecroce (former Patheon CEO).

Direct peers

• Apotex: Canada's largest generic pharmaceutical manufacturer, producing a broad portfolio of generic medicines including complex generics. Directly comparable as a Canadian-based competitor that will likely pursue generic semaglutide and competes for the same domestic payer and patient market.
• Teva Canada: Canadian arm of one of the world's largest generic drug makers, with a strong portfolio in chronic disease. Comparable as a likely entrant into generic semaglutide in Canada and a benchmark for scale and pricing pressure in the Canadian generic market.
• Pharmascience: Major Canadian-owned generic pharmaceutical manufacturer with domestic production capabilities. Comparable to Vimy Pharma as a Canadian-headquartered generic manufacturer targeting the same domestic market with similar chronic-disease therapeutic categories.
• Sandoz Canada: Canadian division of Sandoz, a global leader in generics and biosimilars. Directly comparable as a large-scale competitor in Canadian generic pharmaceuticals, particularly relevant given Sandoz's leadership in biosimilars and complex generics.

Emerging players

• Cipher Pharmaceuticals: Canadian specialty pharmaceutical company focused on commercializing products in chronic disease categories. Comparable to Vimy as a small-to-mid Canadian pharma pursuing specialty and complex generics in similar therapeutic areas.
• HLS Therapeutics: Canadian specialty pharmaceutical company focused on commercializing late-stage products in cardiovascular and CNS. Comparable as a Canadian-headquartered specialty pharma with similar scale and commercial-stage focus on chronic disease.

Broad incumbents

• Novo Nordisk Canada: Innovator of Ozempic (semaglutide) and the dominant GLP-1 player in Canada. Comparable as the incumbent whose patents Vimy is targeting and whose commercial footprint, KOL relationships, and pricing power set the benchmark for any generic entrant.
• Eli Lilly Canada: Canadian arm of Eli Lilly, maker of competing GLP-1 therapies (Mounjaro/Zepbound). Comparable as a broad incumbent in the same therapeutic category and a major competitor for the Canadian diabetes/obesity market that Vimy targets.

Regional players

• Dr. Reddy's Laboratories Canada: Canadian operations of a major India-based global generic manufacturer. Comparable as a likely global generic entrant into Canadian semaglutide with deep manufacturing scale that could undercut Vimy on price.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimy Pharma